Ozempic vs Mounjaro

Ozempic and Mounjaro are both FDA approved for the treatment of type 2 diabetes, both injected once weekly, and both prescribed widely for the glucose-lowering and weight-related benefits they produce. They are often discussed in the same breath, but they are not the same drug.

Ozempic is semaglutide, a selective GLP-1 receptor agonist made by Novo Nordisk. Mounjaro is tirzepatide, a dual GIP / GLP-1 receptor agonist made by Eli Lilly. Both are used to improve glycemic control, but Mounjaro's second receptor target tends to produce larger drops in A1C and larger reductions in body weight at top dose.

For a patient with type 2 diabetes, the choice often comes down to coverage, side effect tolerance, and how aggressive the treatment plan needs to be.

At a glance

How they're alike

Both Ozempic and Mounjaro are once-weekly subcutaneous injections in pre-filled pen devices, administered in the thigh, abdomen, or upper arm. Both are titrated up over several months, both improve A1C, and both produce meaningful weight loss as a secondary benefit even though they are approved for diabetes rather than obesity.

Both work through the incretin pathway: they enhance glucose-dependent insulin release, suppress glucagon, slow gastric emptying, and reduce appetite. Both carry a boxed warning about thyroid C-cell tumors (based on rodent data) and standard cautions about pancreatitis and gallbladder events.

The side effect families overlap. Nausea, constipation, diarrhea, decreased appetite, and fatigue are common during titration on either drug. Both are positioned in modern diabetes guidelines as preferred agents in patients who would benefit from weight loss alongside glycemic control.

How they're different

Mechanism and potency differ. Semaglutide binds the GLP-1 receptor only. Tirzepatide binds both the GIP receptor and the GLP-1 receptor, and in head-to-head trials (SURPASS-2) it produced larger reductions in A1C and body weight than semaglutide at the doses studied. Real-world response varies, but the trial signal is consistent.

Dose ranges differ accordingly. Ozempic tops out at 2.0 mg weekly. Mounjaro is dosed in milligram steps from 2.5 to 15 mg weekly. The wider Mounjaro dose range gives prescribers more room to push for A1C and weight goals — and more room to back off when side effects spike.

Weight loss as a side effect is larger with Mounjaro. The SURMOUNT-1 trial of tirzepatide in obesity (without diabetes) showed roughly 20.9 percent mean body weight loss at 15 mg over 72 weeks, while STEP 1 of semaglutide 2.4 mg showed roughly 14.9 percent at 68 weeks. In diabetes populations the absolute weight loss numbers are smaller for both drugs, but the relative ordering tends to hold.

Which one is right for you?

For someone with type 2 diabetes, the decision is rarely about which drug is universally "best." It's about which one your endocrinologist or primary care provider thinks is the right fit for your A1C target, your tolerance for nausea, your weight-loss goals, and your insurance.

If you have already tried Ozempic and need more glycemic effect or more weight loss, Mounjaro is a common next step. If you tolerated Ozempic well, are at goal, and your plan covers it without friction, switching adds risk without clear benefit. Patients who experience strong gastrointestinal side effects on one drug sometimes do better on the other at a different dose. Bring honest data into the conversation with your provider, including any prior trial of GLP-1 medication.

Common questions

Keep exploring

Browse all GLP-1 guides or compare Wegovy and Zepbound for the weight-loss equivalents.